Literature DB >> 18205978

Retention rate and substance use in methadone and buprenorphine maintenance therapy and predictors of outcome: results from a randomized study.

Michael Soyka1, Christina Zingg, Gabriele Koller, Heinrich Kuefner.   

Abstract

This was a 6-month, randomized, flexible-dose study comparing the effects of methadone (Meth) and buprenorphine (Bup) on retention rate and substance use in a sample of 140 opioid-dependent, primarily heroin-addicted, patients who had been without opioid substitution therapy in the 4 weeks prior to the study. The major aims were to compare the efficacy of Bup and Meth in a flexible dosing regimen and to identify possible predictors of outcome. There were no major inhomogeneities between treatment groups. All patients also received standardized psychosocial interventions. Mean daily dosages after the induction phase were 44-50 mg for Meth and 9-12 mg for Bup. Results from this study indicate a favourable outcome, with an overall retention rate of 52.1% and no significant differences between treatment groups (55.3% vs. 48.4%). Substance use decreased significantly over time in both groups and was non-significantly lower in the Bup group. Predictors of outcome were length of continuous opioid use and age at onset of opioid use, although these were only significant in the Bup group. Mean dosage and other parameters were not significant predictors of outcome. Overall, the results of this study give further evidence that substitution treatment is a safe and effective treatment for drug dependence. Meth and Bup are equally effective. Duration of continuous opioid use and age at onset were found to have predictive value for negative outcome. The intensity of withdrawal symptoms showed the strongest correlation with drop-out. Future studies are warranted to further address patient profiles and outcome under different substitution regimens.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18205978     DOI: 10.1017/S146114570700836X

Source DB:  PubMed          Journal:  Int J Neuropsychopharmacol        ISSN: 1461-1457            Impact factor:   5.176


  58 in total

1.  Patient perspectives on buprenorphine/naloxone: a qualitative study of retention during the starting treatment with agonist replacement therapies (START) study.

Authors:  Cheryl Teruya; Robert P Schwartz; Shannon Gwin Mitchell; Albert L Hasson; Christie Thomas; Samantha H Buoncristiani; Yih-Ing Hser; Katharina Wiest; Allan J Cohen; Naomi Glick; Petra Jacobs; Paul McLaughlin; Walter Ling
Journal:  J Psychoactive Drugs       Date:  2014 Nov-Dec

2.  Comparing buprenorphine induction experience with heroin and prescription opioid users.

Authors:  Suzanne Nielsen; Maureen Hillhouse; Larissa Mooney; Jacqueline Fahey; Walter Ling
Journal:  J Subst Abuse Treat       Date:  2012-02-01

3.  Improving temporal efficiency of outpatient buprenorphine induction.

Authors:  Erik W Gunderson; Frances R Levin; Margaret M Rombone; Suzanne K Vosburg; Herbert D Kleber
Journal:  Am J Addict       Date:  2011-07-18

4.  Buprenorphine Initiation and Linkage to Outpatient Buprenorphine do not Reduce Frequency of Injection Opiate Use Following Hospitalization.

Authors:  Phoebe A Cushman; Jane M Liebschutz; Bradley J Anderson; Merredith R Moreau; Michael D Stein
Journal:  J Subst Abuse Treat       Date:  2016-06-11

5.  Buprenorphine is a weak partial agonist that inhibits opioid receptor desensitization.

Authors:  Michael S Virk; Seksiri Arttamangkul; William T Birdsong; John T Williams
Journal:  J Neurosci       Date:  2009-06-03       Impact factor: 6.167

6.  Effects of lorcaserin on oxycodone self-administration and subjective responses in participants with opioid use disorder.

Authors:  Laura Brandt; Jermaine D Jones; Suky Martinez; Jeanne M Manubay; Shanthi Mogali; Tatiana Ramey; Frances R Levin; Sandra D Comer
Journal:  Drug Alcohol Depend       Date:  2020-01-17       Impact factor: 4.492

7.  Methadone treatment for HIV prevention-feasibility, retention, and predictors of attrition in Dar es Salaam, Tanzania: a retrospective cohort study.

Authors:  Barrot H Lambdin; Frank Masao; Olivia Chang; Pamela Kaduri; Jessie Mbwambo; Ayoub Magimba; Norman Sabuni; R Douglas Bruce
Journal:  Clin Infect Dis       Date:  2014-05-22       Impact factor: 9.079

8.  Emerging adult age status predicts poor buprenorphine treatment retention.

Authors:  Zev Schuman-Olivier; Roger D Weiss; Bettina B Hoeppner; Jacob Borodovsky; Mark J Albanese
Journal:  J Subst Abuse Treat       Date:  2014-05-20

9.  Progression to regular heroin use: examination of patterns, predictors, and consequences.

Authors:  Eric A Woodcock; Leslie H Lundahl; Jonathan J K Stoltman; Mark K Greenwald
Journal:  Addict Behav       Date:  2015-02-26       Impact factor: 3.913

10.  A comparison of buprenorphine taper outcomes between prescription opioid and heroin users.

Authors:  Suzanne Nielsen; Maureen Hillhouse; Christie Thomas; Albert Hasson; Walter Ling
Journal:  J Addict Med       Date:  2013 Jan-Feb       Impact factor: 3.702

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.